Hepatic Disease in HIV-Infected Patients
Summary
- In persons coinfected with HIV and HCV, the prevalence of steatosis ranges from 40% to 70%, with higher rates observed among persons with significant hepatic fibrosis, HCV genotype 3, and exposure to NRTIs didanosine and stavudine[Macías 2012; Sulkowski 2005; Miller 2000; McGovern 2006; Marks 2005]
- HIV-infected patients receiving ART may be at increased risk for the development of NAFLD, particularly in the setting of obesity
- Some HIV-1 PIs have been associated with hyperlipidemia and steatosis as well as insulin resistance and diabetes[Riddle 2001; Carr 1999]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content